Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses

Kenneth Wengler, Xiang He, Anissa Abi-Dargham, Guillermo Horga, Kenneth Wengler, Xiang He, Anissa Abi-Dargham, Guillermo Horga

Abstract

Neuromelanin-sensitive MRI (NM-MRI) provides a noninvasive measure of the content of neuromelanin (NM), a product of dopamine metabolism that accumulates with age in dopamine neurons of the substantia nigra (SN). NM-MRI has been validated as a measure of both dopamine neuron loss, with applications in neurodegenerative disease, and dopamine function, with applications in psychiatric disease. Furthermore, a voxelwise-analysis approach has been validated to resolve substructures, such as the ventral tegmental area (VTA), within midbrain dopaminergic nuclei thought to have distinct anatomical targets and functional roles. NM-MRI is thus a promising tool that could have diverse research and clinical applications to noninvasively interrogate in vivo the dopamine system in neuropsychiatric illness. Although a test-retest reliability study by Langley et al. using the standard NM-MRI protocol recently reported high reliability, a systematic and comprehensive investigation of the performance of the method for various acquisition parameters and preprocessing methods has not been conducted. In particular, most previous studies used relatively thick MRI slices (~3 ​mm), compared to the typical in-plane resolution (~0.5 ​mm) and to the height of the SN (~15 ​mm), to overcome technical limitations such as specific absorption rate and signal-to-noise ratio, at the cost of partial-volume effects. Here, we evaluated the effect of various acquisition and preprocessing parameters on the strength and test-retest reliability of the NM-MRI signal to determine optimized protocols for both region-of-interest (including whole SN-VTA complex and atlas-defined dopaminergic nuclei) and voxelwise measures. Namely, we determined a combination of parameters that optimizes the strength and reliability of the NM-MRI signal, including acquisition time, slice-thickness, spatial-normalization software, and degree of spatial smoothing. Using a newly developed, detailed acquisition protocol, across two scans separated by 13 days on average, we obtained intra-class correlation values indicating excellent reliability and high contrast, which could be achieved with a different set of parameters depending on the measures of interest and experimental constraints such as acquisition time. Based on this, we provide detailed guidelines covering acquisition through analysis and recommendations for performing NM-MRI experiments with high quality and reproducibility. This work provides a foundation for the optimization and standardization of NM-MRI, a promising MRI approach with growing applications throughout clinical and basic neuroscience.

Keywords: NM-MRI; Neuromelanin; Substantia nigra; Test-retest; Ventral tegmental area; Voxelwise analysis.

Conflict of interest statement

Declaration of competing interest The authors declare no conflicts of interest.

Copyright © 2019 Elsevier Inc. All rights reserved.

Figures

Fig. 1.
Fig. 1.
Illustration of the step-by-step procedure for placement of the NM-MRI volume. Yellow lines indicate the position of slices used for placing the volume. (A) Sagittal image showing the greatest separation between the midbrain and thalamus. (B) Coronal plane that identifies the most anterior aspect of the midbrain on the image from A. (C) Axial plane that identifies the inferior aspect of the third ventricle on the image of the coronal plane from B. (D) Location of the axial plane from C identified on the image from A. (E) The axial plane denoting the superior boundary of the NM-MRI volume. This axial plane is the axial plane from D shifted superiorly 3 mm.
Fig. 2.
Fig. 2.
NM-MRI volume placement and NM-MRI images from the 4 NM-MRI sequences tested in this study from a representative subject. (A) Final NM-MRI volume placement. (B–E) Raw signal in axial slices at approximately the same level of the midbrain for each NM-MRI sequence, after motion correction and averaging: (B) NM-1.5 mm, (C) NM-2 mm, (D) NM-3 mm, and (E) NM-3 mm Standard. The intensity scales for the NM-MRI images were set such that the ratio between the lower bound and upper bound was 25%. Red arrows on B – E denote the left SN-VTA complex.
Fig. 3.
Fig. 3.
Spatial normalization and anatomical masks for analysis of NM-MRI images. (A) Average NM-MRI image created by averaging the spatially normalized NM-MRI images from 10 individuals in MNI space. Note the high signal intensity in the SN-VTA complex. (B) Masks for the SN-VTA complex (yellow voxels) and the CC (pink voxels) reference region (used in the calculation of CNR) are overlaid onto the template in A. These anatomical masks were made by manual tracing on a NM-MRI template from a previous study (Cassidy et al., 2019). Note the hyper-intensity along the edge of the midbrain and that the SN-VTA-complex mask does include the anterior medial edge, which is also not included in the probabilistic masks in D. (C) The same average NM-MRI image from A but different slices. (D) Probabilistic masks for the VTA, SNr, SNc, and PBP as defined from a high-resolution probabilistic atlas (Pauli et al., 2018) overlaid onto the template in C. The color scaling for probabilistic masks goes from P = 0.5 (darkest) to P = 0.8 (lightest). Red arrows in A and C denote the left SN-VTA complex.
Fig. 4.
Fig. 4.
ICCROI (top row) and CNRROI (bottom row) within the manually traced mask of the SN-VTA complex (Fig. 3B) as a function of acquisition time. Data points denote the median and error bars indicate the 25th and 75th percentiles.
Fig. 5.
Fig. 5.
ICCASV (top row), ICCWSV (middle row), and CNRV (bottom row) of voxels within the manually traced mask of the SN-VTA complex (Fig. 3B) as a function of acquisition time. Data points denote the median and error bars indicate the 25th and 75th percentiles.
Fig. 6.
Fig. 6.
Scatterplots of ICCASV and CNRV for each of the NM-MRI sequences and spatial normalization software. Each data point represents one voxel within the manually traced mask of the SN-VTA complex (Fig. 3B). The solid lines indicate the linear fit of the relationship between ICCASV and CNRV.
Fig. 7.
Fig. 7.
(A) Predictive value (R2) of anatomical position on ICCASV of voxels within the manually traced mask of the SN-VTA complex (Fig. 3B) for NM-1.5 mm sequence and each of the spatial normalization software. Data points denote the median and error bars indicate the 25th and 75th percentiles. (B) Histogram of ICCASV of voxels within the manually traced mask for NM-1.5 mm sequence and ANTs spatial normalization software, which is the best performing method as per A. (C) Histogram of ICCASV of voxels within the manually traced mask for NM-1.5 mm sequence and SPM12 spatial normalization software, which is the worst performing method as per A. Yellow denotes excellent reliability (ICC over 0.75), orange denotes good reliability (ICC between 0.75 and 0.6), red denotes fair reliability (ICC between 0.6 and 0.4), and burgundy denotes poor reliability (ICC under 0.4).
Fig. 8.
Fig. 8.
The effect of spatial smoothing on ICCASV and CNRV of voxels within the manually traced mask of the SN-VTA complex (Fig. 3B) for different degrees of spatial smoothing. Data points denote the median and error bars show the 25th and 75th percentiles.
Fig. 9.
Fig. 9.
ICCROI (top row) and CNRROI (bottom row) within the probabilistic masks of the dopaminergic nuclei (Fig. 3D) with different probability cutoffs (0.5, 0.6, 0.7, and 0.8) as a function of acquisition time. Data points denote the median and error bars indicate the 25th and 75th percentiles.
Fig. 10.
Fig. 10.
Correlations and histograms of the CNRROI values within the 4 dopaminergic nuclei (Fig. 3D) for the lowest (P = 0.5) and highest (P = 0.8) probability cutoffs. The value within each correlation plot is Spearman’s rho.

References

    1. Abi-Dargham A, Horga G, 2016. The search for imaging biomarkers in psychiatric disorders. Nat. Med 22, 1248.
    1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M, 2000. Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A 97, 8104–8109.
    1. Aiba Y, Sakakibara R, Tsuyusaki Y, Oki T, Ogata T, Tateno F, Terada H, 2019. Neuromelanin-sensitive MRI in the differential diagnosis of elderly white matter lesion from Parkinson’s disease. Neurol. Clin. Neurosci 7, 322–325. 10.1111/ncn3.12320.
    1. Andersson JL, Jenkinson M, Smith S, 2007. Non-linear Registration Aka Spatial Normalisation FMRIB Technial Report TR07JA2. FMRIB Analysis Group of the University of, Oxford.
    1. Ashburner J, 2007. A fast diffeomorphic image registration algorithm. Neuroimage 38, 95–113.
    1. Ashburner J, Friston KJ, 2005. Unified segmentation. Neuroimage 26, 839–851.
    1. Avants BB, Epstein CL, Grossman M, Gee JC, 2008. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med. Image Anal 12, 26–41.
    1. Avants BB, Tustison N, Song G, 2009. Advanced normalization tools (ANTS). Insight j 2, 1–35.
    1. Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, Bellei C, Valmadre A, Vanegas N, Kegeles LS, Brucato G, Jung Kang U, Sulzer D, Zecca L, Abi-Dargham A, Horga G, 2019. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc. Natl. Acad. Sci 116, 5108–5117.
    1. Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, Kanter E, Budhu S, Mandelbaum J, Vonsattel JP, 2014. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun 5, 3633.
    1. Chen X, Huddleston DE, Langley J, Ahn S, Barnum CJ, Factor SA, Levey AI, Hu X, 2014. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn. Reson. Imag 32, 1301–1306.
    1. Cicchetti DV, 1994. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol. Assess 6, 284.
    1. Cowen D, 1986. The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J. Neuropathol. Exp. Neurol 45, 205–221.
    1. Damier P, Hirsch E, Agid Y, Graybiel A, 1999. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122, 1437–1448.
    1. Davis KL, Kahn RS, Ko G, Davidson M, 1991. Dopamine in schizophrenia - a review and reconceptualization. Am. J. Psychiatry 148, 1474–1486.
    1. Depue RA, Collins PF, 1999. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav. Brain Sci 22, 491–517.
    1. Dunlop BW, Nemeroff CB, 2007. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatr 64, 327–337.
    1. Fahn S, Sulzer D, 2004. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1, 139–154.
    1. Fearnley JM, Lees AJ, 1991. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114, 2283–2301.
    1. Fields HL, Hjelmstad GO, Margolis EB, Nicola SM, 2007. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu. Rev. Neurosci 30, 289–316.
    1. Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, Kiefer B, Haase A, 2002. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn. Reson. Med 47, 1202–1210.
    1. Haber S, Ryoo H, Cox C, Lu W, 1995. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol 362, 400–410.
    1. Hatano T, Okuzumi A, Kamagata K, Daida K, Taniguchi D, Hori M, Yoshino H, Aoki S, Hattori N, 2017. Neuromelanin MRI is useful for monitoring motor complications in Parkinson’s and PARK2 disease. J. Neural Transm 124, 407–415.
    1. Hirsch E, Graybiel AM, Agid YA, 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334, 345.
    1. Huddleston DE, Langley J, Sedlacik J, Boelmans K, Factor SA, Hu XP, 2017. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson’s disease. Hum. Brain Mapp 38, 2627–2634.
    1. Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, Zecca L, Costa A, 2016. Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front. Aging Neurosci 8, 196.
    1. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM, 2012. FSL. NeuroImage 62, 782–790.
    1. Kelley AE, Berridge KC, 2002. The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci 22, 3306–3311.
    1. Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, Ito H, Ogawa T, 2013. Correlation between pathology and neuromelanin MR imaging in Parkinson’ s disease and dementia with Lewy bodies. Neuroradiology 55, 947–953.
    1. Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV, 2009. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46, 786–802.
    1. Koob GF, Sanna PP, Bloom FE, 1998. Neuroscience of addiction. Neuron 21, 467–476.
    1. Langley J, Huddleston DE, Chen X, Sedlacik J, Zachariah N, Hu X, 2015. A multicontrast approach for comprehensive imaging of substantia nigra. Neuroimage 112, 7–13.
    1. Langley J, Huddleston DE, Liu CJ, Hu X, 2017. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI. Magn. Reson. Mater. Phys. Biol. Med 30, 121–125.
    1. Laruelle M, Abi-Dargham A, vanDyck CH, Gil R, Dsouza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB, 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A 93, 9235–9240.
    1. Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC, 2004. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J. Comp. Neurol 473, 97–106.
    1. Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, Tomimoto H, 2013. Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur. Neurol 70, 70–77.
    1. Montague PR, Dayan P, Sejnowski TJ, 1996. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J. Neurosci 16, 1936–1947.
    1. Nestler EJ, Carlezon WA Jr., 2006. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151–1159.
    1. Ohtsuka C, Sasaki M, Konno K, Kato K, Takahashi J, Yamashita F, Terayama Y, 2014. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Park. Relat. Disord 20, 755–760.
    1. Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, Takahashi S, Kudo K, Yamashita F, Terayama Y, 2013. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci. Lett 541, 93–98.
    1. Parker DL, Buswell HR, Goodrich KC, Alexander AL, Keck N, Tsuruda JS, 1995. The application of magnetization transfer to MR angiography with reduced total power. Magn. Reson. Med 34, 283–286.
    1. Pauli WM, Nili AN, Tyszka JM, 2018. A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Scientific data 5, 180063.
    1. Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, 2011. Statistical Parametric Mapping: the Analysis of Functional Brain Images. Elsevier.
    1. Robson PM, Grant AK, Madhuranthakam AJ, Lattanzi R, Sodickson DK, McKenzie CA, 2008. Comprehensive quantification of signal-to-noise ratio and g-factor for image-based and k-space-based parallel imaging reconstructions. Magn. Reson. Med 60, 895–907.
    1. Roeper J, 2013. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 36, 336–342.
    1. Sasaki M, Shibata E, Kudo K, Tohyama K, 2008. Neuromelanin-sensitive MRI. Clin. Neuroradiol 18, 147–153.
    1. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A, 2006. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport 17, 1215–1218.
    1. Schultz W, 1998. Predictive reward signal of dopamine neurons. J. Neurophysiol 80, 1–27.
    1. Schultz W, 2007. Behavioral dopamine signals. Trends Neurosci. 30, 203–210.
    1. Schwarz S, Bajaj N, Morgan P, Reid S, Gowland P, Auer D, 2013. Magnetisation transfer contrast to enhance detection of neuromelanin loss at 3T in Parkinson’s disease. Proc. Int. Soc. Mag. Reson. Med 2848.
    1. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP, 2011. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov. Disord 26, 1633–1638.
    1. Shibata E, Sasaki M, Tohyama K, Otsuka K, Endoh J, Terayama Y, Sakai A, 2008. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol. Psychiatry 64, 401–406.
    1. Shrout PE, Fleiss JL, 1979. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull 86, 420.
    1. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, 2000. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci 97, 11869–11874.
    1. Sulzer D, Cassidy C, Horga G, Kang UJ, Fahn S, Casella L, Pezzoli G, Langley J, Hu XP, Zucca FA, 2018. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Parkinson’s disease 4, 11.
    1. Sulzer D, Surmeier DJ, 2013. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov. Disord 28, 715–724.
    1. Sulzer D, Zecca L, 1999. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res 1, 181–195.
    1. Trujillo P, Summers PE, Ferrari E, Zucca FA, Sturini M, Mainardi LT, Cerutti S, Smith AK, Smith SA, Zecca L, 2017. Contrast mechanisms associated with neuromelanin-MRI. Magn. Reson. Med 78, 1790–1800.
    1. Ungless MA, Magill PJ, Bolam JP, 2004. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303, 2040–2042.
    1. Wang J, Huang Z, Li Y, Ye F, Wang C, Zhang Y, Cheng X, Fei G, Liu K, Zeng M, 2019. Neuromelanin-sensitive MRI of the substantia nigra: an imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease. Park. Relat. Disord 58, 3–8.
    1. Wang J, Li Y, Huang Z, Wan W, Zhang Y, Wang C, Cheng X, Ye F, Liu K, Fei G, 2018. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson’ s disease and its phenotypes. Eur. J. Neurol 25, 949–e973.
    1. Watanabe Y, Tanaka H, Tsukabe A, Kunitomi Y, Nishizawa M, Hashimoto R, Yamamori H, Fujimoto M, Fukunaga M, Tomiyama N, 2014. Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia. PLoS One 9, e104619.
    1. Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A, 2017. Pathway-specific dopamine abnormalities in schizophrenia. Biol. Psychiatry 81, 31–42.
    1. Xing Y, Sapuan A, Dineen RA, Auer DP, 2018. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov. Disord 33, 1792–1799.
    1. Yamashita F, Sasaki M, Fukumoto K, Otsuka K, Uwano I, Kameda H, Endoh J, Sakai A, 2016. Detection of changes in the ventral tegmental area of patients with schizophrenia using neuromelanin-sensitive MRI. Neuroreport 27, 289–294.
    1. Zecca L, Bellei C, Costi P, Albertini A, Monzani E, Casella L, Gallorini M, Bergamaschi L, Moscatelli A, Turro NJ, 2008. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci 105, 17567–17572.
    1. Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S, 2000. Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem 74, 1758–1765.
    1. Zecca L, Shima T, Stroppolo A, Goj C, Battiston G, Gerbasi R, Sarna T, Swartz H, 1996. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73, 407–415.
    1. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, 2004. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci 101, 9843–9848.
    1. Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L, 2014. Neuromelanin of the human substantia nigra: an update. Neurotox. Res 25, 13–23.
    1. Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, 2018. Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinson’s disease 4, 17.

Source: PubMed

3
S'abonner